Abstract
Taken together, recent studies make a powerful case for the licensing of aromatase inhibitors in the adjuvant setting, offering an alternative to tamoxifen which has long been the gold standard in breast cancer therapy in the prevention of recurrence.
MeSH terms
-
Antineoplastic Agents, Hormonal / therapeutic use
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / surgery
-
Breast Neoplasms / therapy*
-
Chemotherapy, Adjuvant
-
Female
-
Forecasting
-
Humans
-
Postmenopause
-
Treatment Outcome
Substances
-
Antineoplastic Agents, Hormonal